A recent study suggests a fresh approach to keeping COVID-19 at bay. Conducted by Saarland University in Germany, researchers explored the potential of a nasal spray to significantly cut down the risk of coronavirus infection. This clinical trial, which was part of a phase 2 study published in JAMA Internal Medicine, took place from March 2023 to July 2024 at Saarland University Hospital.
The trial involved 450 healthy adults who were randomly selected to use either the azelastine nasal spray or a placebo three times daily for a total of 56 days. During the study, participants underwent regular SARS-COV-2 rapid antigen tests twice weekly to monitor for infection. For those showing symptoms but testing negative with antigen tests, further PCR tests for respiratory viruses were conducted to ensure accuracy.
Among those using the azelastine nasal spray, only 2.2% contracted COVID-19, a stark contrast to the 6.7% infection rate in the placebo group. This suggests a notable reduction in confirmed COVID infections, as highlighted by the researchers. Additionally, the trial observed an extended duration before infection in participants using the nasal spray.
In addition to reducing COVID-19 infections, the azelastine nasal spray was linked to fewer PCR-confirmed symptomatic infections and a decrease in rhinovirus cases, which often lead to the common cold. Researchers also suggested that azelastine could potentially guard against other respiratory viruses. “In this single-center trial, azelastine nasal spray was associated with reduced risk of SARS-CoV-2 respiratory infections,” the study reported.
Azelastine is not new; it’s been available over the counter for hay fever and is thought to have antiviral properties against COVID-19 and other respiratory viruses. Professor Robert Bals, who led the trial and serves as the director of the Department of Internal Medicine at Saarland University Medical Center, emphasized the real-world implications of the findings. “Azelastine nasal spray could provide an additional, easily accessible prophylactic to complement existing protective measures,” he stated.
The research team advocates for larger trials to further investigate azelastine’s effectiveness as a preventive measure. They are keen on examining its potential against other respiratory pathogens as well. The study underscores the necessity for more comprehensive research to solidify the nasal spray’s role in COVID-19 prevention strategies.
For those interested, more information can be found on Fox News’ health section, where continuous updates on such studies are provided. The study’s insights have sparked a conversation on the need for easily accessible preventive treatments. Fox News Digital has reached out to the study’s researchers for additional comments and insights.
Angelica Stabile, a lifestyle reporter for Fox News Digital, contributed to bringing this study to public attention, highlighting the potential impact of this nasal spray on public health.
